MedTrace Logo

Dynamic Changes in SDF-1α Levels in Acute and Stabilized Heart Disease

NCT02702752 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2020-07-14

No results posted yet for this study

Summary

The aims of the present study are to measure dynamic changes over time in the plasma level of SDF-1α in patients with confirmed diagnoses of AMI, AF and CHF and in so doing:

1. Monitor the plasma level of SDF-1α at the diagnosis, during and after the long term treatment of AMI, AF and CHF. The SDF-1α level of patients is expected to decrease during treatment of the aforementioned conditions.
2. Correlate the plasma level of SDF-1α in relation to clinical, biochemical characteristics of Acute Myocardial Infarction(AMI), Atrial Fibrillation(AF) and Congestive Heart Failure (CHF). In so doing, the investigators expect that SDF-1α will correlate with the severity of heart disease.
3. Study the dynamic of SDF-1α pertaining to its property as prognostic indicator for the long term follow up risk of readmission and mortality of patients diagnosed with AMI, AF or CHF.

Conditions

Interventions

OTHER

DYNASDY

Measurement of SDF-1 alpha levels i patients' blood samples.

Sponsors & Collaborators

  • Copenhagen University Hospital, Hvidovre

    lead OTHER

Principal Investigators

  • Nadia Landex, Ph.D. · Department of Cardiology, Roskilde University Hospital

  • Ema Ema Rastoder, MB · Department of Cardiology, Copenhagen University Hospital Hvidovre

  • Maha Maha Alsawaf, MB · Department of Cardiology, Copenhagen University Hospital Hvidovre

  • Anne Langkilde, MS, Ph.D. · Clinical Research Centre, Copenhagen University Hospital Hvidovre

  • Ove Andersen, M.D., Ph.D. · Clinical Research Centre, Copenhagen University Hospital Hvidovre

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
95 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2016-12-31
Completion
2020-12-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02702752 on ClinicalTrials.gov